Nine More Drugmakers Sign Medicaid Most-Favored-Nation Deals, Bringing White House Total to 26
The Trump administration says the agreements now cover about 89% of the branded drug market, while analysts and Democrats question how much patients will actually save.
Nine Companies, One Question: Whose Discount Was This?
The White House put nine more drug companies on stage on August 31, 2026. Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals and UCB all signed "most-favored-nation" pricing deals[1][2]. That brings the total to 26 drugmakers who've now agreed to give every state Medicaid program their lowest international price, and to use that same benchmark on new drugs launched in the U.S[1][5]. The administration says that's 89% of the branded drug market now under some form of price commitment[1][2].
Nobody disputes that the signings happened, or that they cover a lot of ground: treatments for hemophilia, Parkinson's, macular degeneration, glaucoma, liver disease, skin conditions and several cancers[1][5]. What's disputed is a much narrower question, and it's one both sides can state in a single sentence without disagreeing on the wording: how much does a Medicaid-only price cut actually save anyone, when Medicaid was already the cheapest buyer in the country before any deal was signed?
The Discount Nobody Had to Give
Here's the fact that sits underneath the whole fight. Federal law already forces brand-name drugmakers to give Medicaid a rebate of at least 23.1% off the average price they charge, or to match the lowest price they give any private buyer, whichever cuts deeper[9][10]. That's not new, and it's not part of these deals. It's been the law for years, and it makes Medicaid the lowest-priced payer in the U.S. by statute, before a single new agreement gets signed.
That matters because it sets the size of the concession these companies are actually making. Medicare, the program covering seniors, and employer health plans, which is where most of the industry's American revenue comes from, are untouched by any of this[4]. So when a company agrees to extend a "most-favored-nation" price to Medicaid, it's agreeing to discount the payer that was already getting the best deal, while leaving the biggest slice of its U.S. business exactly where it was.
The administration's response isn't to deny that math — it's to say the math misses the point. Officials argue that for many newer specialty drugs, the price charged in Europe is still lower than what Medicaid pays even after existing rebates, so the new benchmark does bite in some cases[1]. And they put more weight on the forward-looking half of the deal: locking in most-favored-nation pricing for drugs that haven't launched yet, before the U.S. price gets set high in the first place[1].
What's Actually Buying the Signature
If Medicaid savings are modest, why are 26 companies lining up to sign? The answer sits in a different federal power entirely. The administration has ordered tariffs of up to 100% on some branded drug imports, using a trade law called Section 232, which lets a president restrict imports on national-security grounds without needing a vote in Congress[5][20]. Companies that sign these pricing deals get relief from that tariff threat.
Sun Pharma, based in India, said its agreement delays Section 232 tariffs on its innovative products for more than two years[7][8]. That's the trade, laid bare: a price concession on the cheapest payer, in exchange for years of certainty against a tariff that could otherwise run as high as 100% on imported drugs. Indian business outlets covering Sun Pharma's deal wrote almost entirely from that angle — protecting export access to the U.S. market, with barely a mention of American patients at all[7][8].
There's a hard deadline attached. The president has said companies that don't sign voluntarily will face "every tool in our arsenal" after September 29, 2026[5]. Nine of the signing companies also pledged $19.6 billion in U.S. manufacturing investment, and some are contributing raw drug ingredients — Sun Pharma promised 71.4 tons of clindamycin and 6.75 tons of doxycycline, Teva pledged 45 metric tons of metronidazole and 4.8 tons of amlodipine — to a strategic reserve meant to guard against supply shortages[1][2][7][8].
The Number Nobody Can Check
Here's where the story runs into a wall. The Centers for Medicare and Medicaid Services, the federal agency that runs Medicaid, has said the new pricing only kicks in where a state's current after-rebate price is already higher than the new benchmark[9]. And those after-rebate prices — what a state actually pays once existing discounts are applied — are confidential by law. Manufacturers will report them voluntarily, but there's no outside dataset to check the numbers against[9].
That means the 89% market-coverage figure and the skeptics' doubts about it are both, right now, unfalsifiable. Researchers at Georgetown University's Center for Children and Families have asked directly whether states will see any savings at all, since the deal terms themselves aren't public[11]. Wall Street read the announcement as minor: shares of most of the nine companies closed roughly flat the following Monday, with Teva and BeOne down about 1%[2].
Industry analysts told the health-news outlet STAT that they see the pattern of announcements as timed messaging ahead of the 2026 midterm elections, when drug prices are likely to be a major issue for voters[4]. That doesn't mean the deals aren't real. It means the pace and staging of them line up with a political calendar as much as with a policy rollout.
Two Kinds of Objection, From Opposite Directions
Congressional Democrats and progressive health groups have a different complaint than "it's too small." They point to the 2022 law letting Medicare negotiate drug prices directly, an achievement they argue this administration has attacked while claiming credit for a smaller, voluntary version of the same idea[12][18]. They also fold in a separate fight — Medicaid and Affordable Care Act enrollment losses under a recent Republican budget law — arguing that coverage lost outweighs any discount gained[12]. Senate Democrats have already demanded the underlying deal terms be made public[12].
A second objection comes from an unlikely direction: free-trade conservatives and business-press critics who broadly support lower drug prices but object to how they're being extracted. The Wall Street Journal's editorial board wrote in a July 2026 editorial about Trump's tariff strategy generally — not specifically about the pharma deals — that it shows "how the President wields tariffs to coerce policy outcomes he can't get through Congress"[19]. That critique extends naturally to the pharma tariff threat, even though it wasn't written about this announcement. Their argument is about method, not outcome: if the price benchmark is good policy, it should pass as a law, not get extracted by threatening a 100% import tax[19].
That gives the coercion argument backing from both the left and parts of the right, which is unusual, and it raises the odds this approach eventually faces a court challenge or congressional pushback[19].
How the Coverage Split
Outlets covered this almost entirely along the lines you'd expect, with the disagreement showing up in which fact got the headline. The Washington Examiner and RedState led with the White House's own framing — the president delivering what Congress couldn't, with the 89% figure stated as an achieved result rather than a count of signatures[13][14]. Fox News described the surrounding tariff policy as an "America First push," adopting the administration's own language[20].
STAT, a health-industry trade outlet, took the opposite entry point, headlining its piece around analysts calling the announcements "headline-grabbing midterm messaging" before laying out the deal terms[4]. Common Dreams, writing from a progressive advocacy stance, called the deals a distraction and wove in the separate ACA and Medicaid coverage cuts, which shifts the story from whether the deals work to whether the administration is acting in patients' interest[12]. CNBC's business-focused coverage noted the flat stock reaction without stating outright what that implies — that markets priced this as a low-cost move for the companies involved[2].
What's left standing after all of that is the one number that would actually settle the argument: what a state Medicaid program pays for these drugs, before the deal and after. Rebate figures stay confidential, CMS reporting stays voluntary, and the September 29 deadline for holdout companies is still ahead[9][11]. Until that number surfaces, both the White House's claim and its critics' doubts remain arguments, not proof.
Summary
On August 31, 2026, the White House announced that nine more drug companies had signed "most-favored-nation" pricing agreements[1][2]. The nine are Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals and UCB[1]. That brings the total to 26 manufacturers, which the administration says covers about 89% of the branded drug market[1][2]. Under the deals, each company agrees to offer every state Medicaid program the lowest price it charges in other wealthy countries, and to use that benchmark for new U.S. drug launches[5].
The deals are voluntary, but they are not made in a vacuum. The administration has ordered tariffs of up to 100% on some branded drug imports under Section 232, a trade law that lets a president restrict imports on national-security grounds[20]. Companies that sign get relief from those tariffs. Sun Pharma said its deal delays Section 232 tariffs on its innovative products for more than two years[7][8]. The president has said non-signers face "every tool in our arsenal" after a September 29, 2026 deadline[5].
The central dispute is not whether the signings happened. It is whether Medicaid is the place where a price cut matters. Medicaid already gets the lowest price required by U.S. law: brand manufacturers must give it at least 23.1% off the average manufacturer price, or match the best price offered to any private buyer, whichever is larger[9][10]. Analysts argue that cutting there is cheap for drugmakers, while Medicare and employer insurance prices go untouched[4]. STAT reported that industry analysts read the announcements as headline-grabbing messaging ahead of the midterm elections[4]. The administration counters that for many newer specialty drugs, European prices sit below even the U.S. Medicaid net price, and that locking MFN onto future launches stops high prices before they start[1][5].
How much any state saves is still not public. CMS has said MFN pricing applies only where a state's current after-rebate price is above the MFN price, and that manufacturers will report those net prices voluntarily[9]. Rebate figures are confidential, so no outside dataset exists to check the claim[9]. Shares of most of the nine companies closed roughly flat the following Monday; Teva and BeOne fell about 1%[2].
The Event
On August 31, 2026, the White House announced most-favored-nation drug pricing agreements with nine additional pharmaceutical manufacturers: Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals and UCB[1][2]. A signing ceremony was held at the White House, with Sun Pharma confirming its participation on September 1[7]. The administration said the agreements bring the total to 26 manufacturers covering about 89% of the branded drug market[1]. Under the terms, each company will make most-favored-nation prices available to every state Medicaid program and apply the benchmark to newly launched medicines in the United States[5].
Undisputed Facts
- The nine manufacturers announced on August 31, 2026 are Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals and UCB[1][2].
- The White House says the agreements bring total participants to 26 manufacturers, covering about 89% of the branded drug market[1][2].
- The agreements cover Medicaid pricing and future U.S. launches; they do not change Medicare or commercial insurance prices[4][5].
- The drugs involved treat conditions including hemophilia, Parkinson's disease, macular degeneration, glaucoma, liver disease, skin conditions and several cancers[1][5].
- Federal law already requires brand manufacturers to pay Medicaid a rebate of at least 23.1% of the average manufacturer price, or the difference between that price and the lowest price given any private buyer, whichever is greater[9][10].
- The administration has imposed tariffs of up to 100% on some branded drug imports under Section 232 of the Trade Expansion Act of 1962, and companies signing MFN deals receive relief from that exposure[5][20].
- Sun Pharma said its agreement delays Section 232 tariffs on its innovative pharmaceutical products for more than two years, and that it will contribute 71.4 tons of clindamycin and 6.75 tons of doxycycline to a strategic active pharmaceutical ingredient reserve[7][8].
- Teva agreed to contribute 45 metric tons of metronidazole and 4.8 tons of amlodipine to the same reserve[2].
- Trade press reported the nine companies together pledged $19.6 billion in U.S. manufacturing investment[6].
- The president set a September 29, 2026 deadline, saying manufacturers that do not voluntarily lower prices will face "every tool in our arsenal"[5].
- Shares of most of the nine companies closed roughly flat the following Monday, with Teva and BeOne down about 1%[2].
The Pressure
Strip away the moralizing and blame. What structural realities persist regardless of which narrative wins?
- Medicaid is the cheapest concession available
- By law, brand manufacturers already owe Medicaid at least 23.1% off the average manufacturer price, or must match the lowest price they give any private buyer, whichever is bigger[9][10]. That makes Medicaid the lowest-priced U.S. payer before any deal is signed. So a Medicaid-only price commitment costs a drugmaker far less than one touching Medicare or employer plans, where most branded revenue actually sits[4].
- Tariff leverage replaces legislation
- Section 232 lets a president restrict imports on national-security grounds without a vote in Congress[20]. Pairing a tariff threat with an exemption for signers produces policy outcomes a bill could not pass. That is why the objection to the method comes from both the left and from free-market conservatives[19].
- The savings cannot be independently checked
- Drug rebates are confidential, so no public dataset shows what states pay after rebates[9]. CMS has said manufacturers will report those net prices voluntarily[9]. Whichever side is right about savings, neither can currently prove it with public data — and that opacity favors whoever announces first.
- The election calendar
- Drug costs poll well for whoever appears to be acting on them. Analysts told STAT the timing points toward the midterms[4]. That does not make the deals fake; it does explain the pace of announcements and the ceremony format.
Material realityTwenty-six manufacturers have signed agreements that lower what state Medicaid programs pay for certain branded drugs and set a most-favored-nation benchmark for future U.S. launches[1][5]. Medicare and employer insurance prices are unchanged by these deals[4]. Medicaid was already the lowest-priced U.S. payer by statute, so the incremental discount is real but narrow, and its size is not public[9][10][11]. In exchange, signers get relief from Section 232 tariffs of up to 100% on branded imports — a benefit that is large, immediate and easy to value, unlike the savings[7][8][20]. Nine companies also pledged $19.6 billion in U.S. manufacturing and contributed antibiotic ingredients to a strategic reserve[2][6]. Investors priced the deals as minor: most of the nine closed roughly flat, with Teva and BeOne down about 1%[2]. A hard date sits ahead — September 29, 2026 — after which the administration says non-signers face further action[5].
Narrative as a weaponThe White House is the loudest voice here and wants you to count signatures: 26 companies, 89% of the branded market, a problem solved by deal-making instead of legislation[1]. Drugmakers want you to see cooperation, not capitulation — signing lets them avoid tariffs and a mandatory Medicare rule while conceding in the one program where the discount costs them least[4][7]. Democrats and progressive groups want you to see ceremony without substance, and to credit Medicare negotiation instead[12][18]. Free-trade conservatives, including the Wall Street Journal's editorial board, want you to focus on the method rather than the result, calling tariff leverage a way around Congress[19]. Overseas business press wants readers at home to see a tariff shield secured[7][8]. The one thing no one can show you is the number that would settle it: what a state Medicaid program actually pays after rebates, before and after[9][11].
How Each Side Sees It
Each major actor’s view — how it frames things, its underlying incentive, and how it’s materially affected. Tap a side to read it.
Frames it asAmericans pay far more than Europeans for the same pills made in the same plants, and past administrations accepted it. The fix is simple and fair: if a drugmaker sells a medicine cheaper in Germany, it must offer that price here too[1]. Twenty-six companies signing in about a year is more movement than decades of legislation produced[1][13]. On the objection that Medicaid is already cheap, the administration's answer is that for many newer specialty drugs the European price still sits below the U.S. Medicaid net price, so the benchmark does bind[1]. And the forward-looking piece matters more than the back catalog: applying MFN to future launches stops a high U.S. launch price from ever being set. The administration also argues that pairing price commitments with tariff relief and U.S. manufacturing pledges fixes two problems at once — cost and supply-chain dependence[1][6][20].
WhyDeliver a visible win on an issue voters consistently rank high, before the 2026 midterms, without needing a bill through Congress[4]. Voluntary deals also avoid the litigation risk that sank an earlier mandatory MFN rule[1].
Impact on themPolitically, each signing is a televised event with CEOs present. Legally, the voluntary structure is far harder to challenge in court than a regulation. The risk is that if state Medicaid savings stay unpublished or turn out small, the 89% figure becomes a liability rather than an asset[11].
Frames it asSigning is risk management, not surrender. A tariff of up to 100% on branded imports would be far more damaging than a Medicaid concession, so trading a small discount for multi-year tariff certainty is rational[7][8][20]. Companies also argue their real objection was always to price controls in Medicare and the commercial market, where most of their U.S. revenue sits — and those were left alone[4]. Third, they say the U.S.-Europe price gap exists because Europe's single-payer systems refuse to pay for innovation, and that forcing U.S. prices down to that level without changing European behavior means less research money, not fairer burden-sharing.
WhyBuy predictability. Avoid a mandatory Medicare MFN rule, secure tariff exemptions, protect launch prices in the largest market on earth, and stay on good terms with an administration that controls approvals and trade policy.
Impact on themMedicaid is a small slice of branded revenue, so the near-term hit is modest. Overseas manufacturers gain the most: Sun Pharma locked in more than two years of tariff delay for its innovative products[7][8]. Investors read the deals as mild — most of the nine traded roughly flat, with Teva and BeOne off about 1%[2].
Frames it asThe scope, not the sincerity, is the problem. Medicaid is already the cheapest U.S. payer by statute, so a discount there is the least expensive concession a drugmaker can make[9][10]. Analysts told STAT the announcements read as messaging aimed at the midterms[4]. CMS has said MFN prices apply only where a state's current after-rebate price is already higher than the MFN price — and since rebate amounts are confidential, no outside dataset can verify how often that is true[9]. Georgetown researchers have asked whether states will see any savings at all, and note the terms are not public[11]. The related consumer site, TrumpRx, drew similar criticism: NPR reported it offered a narrow selection rather than broad discounts, and a New York Times comparison found its "world's lowest price" claims did not hold up[16][17].
WhyProfessional credibility rests on measurable outcomes. State budget officials need to know what will actually land in their line items before they plan around it.
Impact on themIf net-price data stays voluntary and confidential, no one outside CMS and the manufacturers can audit the savings claim. That leaves both the 89% figure and the skeptics' rebuttal unfalsifiable in public.
Frames it asThey argue the real cost cuts came from the 2022 law that lets Medicare negotiate prices directly, which the administration has attacked, and that these voluntary deals are being used to claim credit for it[12][18]. Their second point is scope: the deals leave Medicare and employer coverage alone, so most insured Americans see nothing change[4][12]. Third, they argue secrecy defeats accountability — agreements whose terms are not published cannot be enforced by anyone but the signers[11][12]. They also place the announcements against Medicaid and ACA enrollment losses under the Republican budget law, arguing coverage lost outweighs any discount gained[12].
WhyProtect Medicare negotiation as a Democratic achievement and deny the administration a clean drug-pricing win going into the midterms.
Impact on themTheir strongest lever is oversight: Senate Democrats have already demanded the underlying deal terms[12]. Their weakness is that the signings are real and visible, while their counterargument requires explaining a rebate formula.
Frames it asThis camp supports lower drug prices but objects to the method. The Wall Street Journal's editorial board has separately criticized Trump's tariff strategy on these grounds — writing in a July 2026 editorial that it shows 'how the President wields tariffs to coerce policy outcomes he can't get through Congress'[19]. The principle is constitutional, not partisan: if price benchmarks are good policy, they should pass as law, not be extracted under threat of a 100% import tax. They also warn that using tariffs as a bargaining chip on medicines makes supply chains less stable, not more.
WhyDefend legislative authority over trade and pricing, and defend a rules-based market against deal-by-deal presidential bargaining.
Impact on themThis split matters because it means opposition is not only from the left. It gives the coercion critique cross-ideological standing, which raises the odds of court challenges or congressional pushback later.
Like this article?
The Bias Ledger average rating 5
The same story, as framed by outlets across the spectrum, ordered least to most biased. The bias score (1 = straight, 10 = heavily spun) is an AI assessment of that framing — click an outlet to see its track record. The tell is the word choice or omission that reveals the angle.
| Outlet | Vantage | Bias | How they frame it | The tell |
|---|---|---|---|---|
| CNBC | U.S. center (business) | 2 | "Trump strikes new drug pricing deals with nine midsized drugmakers" — reports the list, the terms, the reserve contributions and the share-price reaction. | Frames the story through investor impact. Noting that shares closed roughly flat is neutral reporting, but it quietly signals that markets see little cost to the companies — a judgment the piece never states outright. |
| Business Today | Indian business press | 3 | "How Sun Pharma is avoiding a tariff hit by agreeing to MFN pricing for US Medicaid" — the deal as a defensive trade move by an Indian exporter. | Names the incentive that U.S. coverage often leaves implicit: the price concession is the fee for tariff protection. American patients are essentially absent from the story, which is its own kind of narrowing. |
| STAT | U.S. center (health/industry trade) | 4 | "Analysts call Trump drug price moves headline-grabbing midterm messaging" — leads with the skeptics rather than the announcement. | Puts an analyst characterization in the headline. It is attributed and sourced, but choosing "midterm messaging" as the frame decides the story's meaning before the reader sees the terms. |
| Washington Examiner | U.S. right | 5 | "Trump announces nine most-favored-nation deals to lower drug prices" — the president as the actor, price reduction as the accomplished result. | The headline states the purpose as the outcome. The Medicaid-only scope, which is the whole of the analysts' objection, is not what the framing foregrounds. |
| Fox News | U.S. right | 6 | Covers the surrounding tariff policy as an "America First push" on drug imports. | "America First push" adopts the administration's own campaign language as descriptive shorthand. The coercion objection — including the one from the Wall Street Journal's editorial board — is not the frame. |
| RedState (Opinion) | U.S. right (commentary) | 7 | "Trump's Drug Pricing Push Now Covers 89 Percent of Branded Market" — the White House's own coverage figure as the headline fact. | Uses "covers" for what is a count of participating manufacturers, not a measure of prescriptions repriced. The number comes from the administration and is presented without that attribution. |
| Common Dreams | U.S. progressive advocacy | 8 | "Trump Pharma Deals Called Distraction From 'Failed Plan to Lower US Drug Prices'" — the deals as theater covering a failure. | Sources the verdict to critics via quotation marks, then builds the piece entirely from those critics. It also folds in ACA and Medicaid coverage losses, which are a separate policy fight, making the deals look worse by association. |
References
- Fact Sheet: President Donald J. Trump Announces Deal with Nine Additional Pharmaceutical Manufacturers to Lower Drug Prices for Americans — The White House · U.S. executive branch — the announcing party; primary source for the deal terms and the 89% claim
- Trump strikes new drug pricing deals with nine midsized drugmakers — CNBC · U.S. business news, Comcast/NBCUniversal-owned; investor-oriented framing
- Trump says more drug companies agree to voluntarily lower drug prices — STAT · U.S. health and biotech trade publication, owned by Boston Globe Media
- Analysts call Trump drug price moves headline-grabbing midterm messaging — STAT · U.S. health and biotech trade publication; sources Wall Street sell-side analysts covering pharma
- MFN Goes Mid-Market: Nine More Drugmakers Sign Medicaid Pricing Deals as the September 29 Tariff Deadline Approaches — Gibson Dunn · Corporate law firm client alert; advises pharmaceutical and investor clients, so written from the regulated industry's vantage
- MFN Program Grows to 26 Drugmakers as Nine More Commit to $19.6B in US Manufacturing — Pharmaceutical Commerce · U.S. pharmaceutical industry trade press
- How Sun Pharma is avoiding a tariff hit by agreeing to MFN pricing for US Medicaid — Business Today · Indian business magazine, India Today Group; domestic-exporter perspective
- Sun Pharma Agrees to US 'Most Favoured Nation' Drug Pricing, Secures 2-Year Tariff Delay — Medical Dialogues · Indian medical and pharma trade outlet
- The Best Price Requirement of the Medicaid Rebate Program — Academy of Managed Care Pharmacy · U.S. professional association of managed-care pharmacists; represents payers and pharmacy benefit managers, not manufacturers
- Medicaid Drug Rebate Program — Wikipedia · Crowd-edited reference; used here only for the statutory 23.1% brand rebate formula, which is set in federal law
- Many Unanswered Questions: Will the Trump Administration's Drug Pricing Deals Result in Any Cost Savings for State Medicaid Programs? — Georgetown University Center for Children and Families · University research center that advocates for expanded public health coverage; left-of-center on Medicaid policy
- Trump Pharma Deals Called Distraction From 'Failed Plan to Lower US Drug Prices' — Common Dreams · U.S. progressive nonprofit news site; explicitly left advocacy, donor-funded
- Trump announces nine most-favored-nation deals to lower drug prices — Washington Examiner · U.S. conservative outlet
- Trump's Drug Pricing Push Now Covers 89 Percent of Branded Market — RedState · U.S. conservative commentary site (Salem Media)
- What Trump's Most-Favored-Nation Deal Means for Drug Prices — TIME · U.S. mainstream newsmagazine, center to center-left
- TrumpRx promised a supermarket for cheaper drugs but delivered a boutique — NPR · U.S. public radio; center-left audience, partly listener- and grant-funded
- TrumpRx's 'world's lowest' drug price claims fall short in global comparison: NYT — Fierce Pharma · U.S. pharmaceutical industry trade press; summarizing a New York Times price comparison
- Trump Claims Credit for Drug Price Decline. Experts Say It's More Complicated. — FactCheck.org · U.S. fact-checking project of the Annenberg Public Policy Center, University of Pennsylvania
- WSJ editorial board rips into Trump's latest tariff 'obsession' — The Hill · U.S. centrist political outlet; reporting on a Wall Street Journal editorial-board opinion piece
- Trump targets drug imports with tariffs up to 100% — Fox News · U.S. conservative broadcast and digital news
- Savings from Most-Favored-Nation (MFN) Drug Pricing Policy — Council of Economic Advisers, The White House · U.S. executive branch economic office; the administration's own savings estimate
- Nine more drugmakers cut pricing deals with Trump — Axios · U.S. center; brief-format political and policy news
- Analysis: 5 burning questions on Trump's latest MFN drug price moves — STAT · U.S. health and biotech trade publication; signed analysis piece
- White House unveils next round of MFN pricing deals with 9 midsized drugmakers — Fierce Pharma · U.S. pharmaceutical industry trade press